Click on a filter below to refine your search. Remove a filter to broaden your search.
Metabolic agents were the most costly category; antidiabetic agents were the mostly costly therapeutic area.
Supply disruptions increased for drugs with and without reports at the start of the COVID-19 pandemic.
Larger reductions were seen in heart failure-related symptoms and physical limitations for patients with HFpEF and type 2 diabetes.
The time to sustained alleviation of COVID-19 symptoms was not significantly shorter with nirmatrelvir-ritonavir versus placebo.
Lixisenatide results in less progression of motor disability than placebo at 12 months for individuals with early Parkinson’s disease.
Caps are associated with a reduction in insulin costs, mainly driven by patients enrolled in health savings accounts.
Medicare will now cover the popular weight-loss drug Wegovy if patients using it also have heart disease, US officials announced Thursday.
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.
The findings seen among adults of all ages, especially those aged 85 years or older; the risk was highest in the first 28 days after initiation.
During high-concentration capsaicin patch treatment, a significant decrease was seen in average daily morphine equivalent dose.